Luebeck

• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting
  2023-507129-40-00 4 2024-08-06 interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients Recruiting
  2022-501157-36-00 6 2024-02-07 Critically ill patients who are dependent on high level medical care i
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• OLE study in participants with pulmonary arterial hypertension Recruiting
  2023-505539-11-00 10 2023-04-06 Pulmonary Arterial Hypertension
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting
  2023-505766-28-00 10 2022-10-10 Hereditary angioedema
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI) … Recruiting
  2024-518195-31-00 6 2021-09-29 acute myocardial infarction
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo Recruiting
  2025-522301-37-00 4 2026-06-24 Nonsegmental vitiligo
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Recruiting
  2025-524078-40-00 5 2026-06-10 Chronic Spontaneous Urticaria
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Recruiting
  2025-523461-17-01 5 2026-06-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting
  2025-523602-33-00 9 2026-05-13 Advanced or unresectable Hepatocellular Carcinoma (HCC)
• Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial (FEMIT … Recruiting
  2025-520452-28-00 4 2026-05-12 Recurrent urinary tract infections (rUTI)
• Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS) Recruiting
  2025-524002-16-00 5 2026-05-12 Amyotrophic Lateral Sclerosis
• A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-0 … Recruiting
  2025-524987-39-00 3 2026-05-04 Mild to Moderate Asthma
• Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting
  2025-521865-29-00 4 2026-04-30 moderate-to-severe hidradenitis suppurativa
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic … Recruiting
  2025-522705-37-00 4 2026-04-21 HIDRADENITIS SUPPURATIVA
• A study to assess NAV-240 in adult participants with Hidradenitis Suppurativa Recruiting
  2025-523557-33-00 4 2026-04-20 Moderate-to-Severe Hidradenitis Suppurativa
• Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting
  2025-522583-32-00 5 2026-04-13 Cold-Induced Urticaria and Symptomatic Dermographism

Showing 49–72 of 288 trials